[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580197":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":27,"locations":33,"responsibleParty":123,"collaborators":11,"id":125,"slug":126,"hasResults":127,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":11,"eligibilityCriteria":131,"healthyVolunteers":127,"sex":132,"minAge":133,"maxAge":11,"enrollmentInfo":134,"targetDuration":11,"studyType":137,"phases":138,"briefSummary":140,"conditions":141,"keywords":11,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":152},{"fullName":5,"class":6},"ARS Pharmaceuticals, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Neffy","ACTIVE_COMPARATOR",null,[13],"Drug: Neffy",{"label":15,"type":10,"description":11,"interventionNames":16},"IM adrenaline",[17],"Drug: Adrenaline",[19,23],{"type":20,"name":9,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","Epinephrine nasal spray",[9],{"type":20,"name":24,"description":25,"armGroupLabels":26,"otherNames":11},"Adrenaline","Epinephrine injection",[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Osnat Ehrman, MSc.","CONTACT","952.334.5797","osnate@pacificlinkconsulting.com",[34,54,67,80,93,107],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Orso Health, Inc.","RECRUITING","La Jolla","California","92037","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-117.2742,32.84727,{"lat":46,"lon":45},[49,51],{"name":50,"role":30,"phone":11,"phoneExt":11,"email":11},"Investigator, MD",{"name":52,"role":53,"phone":11,"phoneExt":11,"email":11},"Ali Doroudchi, MD","PRINCIPAL_INVESTIGATOR",{"facility":55,"status":36,"city":56,"state":57,"zip":58,"country":40,"countryCode":41,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Children's National Hospital","Washington D.C.","District of Columbia","20010",{"type":43,"coordinates":60},[61,62],-77.03637,38.89511,{"lat":62,"lon":61},[65],{"name":66,"role":30,"phone":11,"phoneExt":11,"email":11},"Ammara Ahmed, DO",{"facility":68,"status":36,"city":69,"state":70,"zip":71,"country":40,"countryCode":41,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Endeavor Health","Glenview","Illinois","60026",{"type":43,"coordinates":73},[74,75],-87.78784,42.06975,{"lat":75,"lon":74},[78],{"name":79,"role":30,"phone":11,"phoneExt":11,"email":11},"Giselle Mosnaim, MD",{"facility":81,"status":36,"city":82,"state":83,"zip":84,"country":40,"countryCode":41,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"University Of Michigan","Ann Arbor","Michigan","48105",{"type":43,"coordinates":86},[87,88],-83.74088,42.27756,{"lat":88,"lon":87},[91],{"name":92,"role":30,"phone":11,"phoneExt":11,"email":11},"Ian Slack, MD",{"facility":94,"status":36,"city":95,"state":95,"zip":96,"country":40,"countryCode":41,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"Weill Cornell Medicine\u002FNewYork Presbyterian Hospital","New York","10021",{"type":43,"coordinates":98},[99,100],-74.00597,40.71427,{"lat":100,"lon":99},[103],{"name":104,"role":30,"phone":105,"phoneExt":11,"email":106},"Miriam Samstein, M.D, Ph.D.","347-834-3746","mb.eichenbaum@gmail.com",{"facility":108,"status":36,"city":109,"state":110,"zip":111,"country":40,"countryCode":41,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"Cincinnati Children's Hospital Medical Center","Cincinnati","Ohio","45229",{"type":43,"coordinates":113},[114,115],-84.51439,39.12711,{"lat":115,"lon":114},[118,121],{"name":50,"role":30,"phone":119,"phoneExt":11,"email":120},"513-517-1179","Yasmin.hassoun@cchmc.org",{"name":122,"role":53,"phone":11,"phoneExt":11,"email":11},"Yasmin Hassoun, MD",{"type":124,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100580197","phase-4-study-evaluating-the-safety-and-efficacy-of-neffy-or-intramuscular-adrenalin-in-patients-with-allergic-reactions-after-oral-food-challenge-or-allergen-immunotherapy-100580197",false,"NCT06834165","Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy","A Phase IV Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy","Inclusion Criteria:\n\n* Is a patient 4 years old or greater, inclusive, who are scheduled to undergo OFC, AIT, or other relevant allergy challenge.\n* Has body weight 15 kg or greater at the time of allergy challenge.\n* Is willing and able to provide written informed consent prior to participating in the study. In the case of minors (\\\u003C18 years old), assent can be obtained from his\u002Fher legal representative, and as much possible from the patient himself\u002Fherself.\n* Patient experiences an allergic reaction that, in the opinion of the Investigator, requires treatment with epinephrine via neffy or IM Adrenalin.\n\nExclusion Criteria:\n\n\\- Has any clinically significant medical condition that precludes treatment with epinephrine as assessed by the Investigator.","ALL","4 Years",{"count":135,"type":136},600,"ESTIMATED","INTERVENTIONAL",[139],"PHASE4","The study is to assess the safety of neffy or IM Adrenalin in patients who are experiencing allergic reactions after an OFC, allergen Immunotherapy (AIT), or other allergy challenge that may require epinephrine intervention.",[142],"Allergic Reactions","2026-04-20",{"date":145,"type":146},"2026-04-21","ACTUAL",{"date":148,"type":146},"2025-05-20",{"date":150,"type":136},"2027-06",{"name":5,"class":6},6]